
FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC
Key Takeaways
- FDA accelerated approval covers ALK-positive NSCLC after alectinib, or after ≥2 prior ALK TKIs plus platinum chemotherapy in unresectable locally advanced or metastatic disease.
- ALKOVE-1 post-alectinib cohort (n=67) demonstrated 49% ORR, with 76% of responders maintaining DOR ≥6 months and 5% maintaining DOR ≥12 months.
The FDA has approved neladalkib for previously treated, ALK-positive, locally adanced or metastatic non-small cell lung cancer.
The FDA has granted accelerated approval to neladalkib (Nelkarmi) for patients with locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC) who have been previously treated in the unresectable locally advanced or metastatic setting with either a prior ALK-directed TKI consisting of alectinib (Alecensa), or 2 or more prior ALK-directed TKIs and platinum-based chemotherapy.1
The approval was supported by data from the phase 1/2 ALKOVE-1 study (NCT05384626) where patients who received a prior ALK-directed TKI consisting of alectinib (n = 67) achieved an overall response rate (ORR) of 49% (95% CI; 37%-62%), alongside 76% of patients having a duration of response (DOR) that was 6 months or longer and 5% had a DOR of 12 months or longer.
Moreover, patients who received two or more prior ALK TKIs and platinum-based chemotherapy (n = 155), achieved an ORR of 32% (95% CI; 24%-40%), with 69% and 51% achieving DORs of at least 6 and 12 months, respectively.
Related to this article








